Merus said that the portfolio of products include anti-fungal creams and also certain wound care products such as Hydrogel, ulcer wound, and composite multi-layered dressings
Ahmad Doroudian, president and CEO of Merus, said: “Methapharm is expected to provide Merus with the infrastructure, and regulatory expertise in order to propel the company into the future. We look forward to the expansion of our partnership with Methapharm in the near future.”
Methapharm is a cGMP specialty pharmaceutical company into the commercialisation and marketing of niche pharmaceutical products and devices in specific therapeutic categories. The company markets its own proprietary products as well as products from partner companies.